Fong L - Search Results

1

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.

Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. Friedlander TW, et al. Among authors: fong l. Clin Genitourin Cancer. 2017 Dec;15(6):733-741.e1. doi: 10.1016/j.clgc.2017.05.026. Epub 2017 Jun 3. Clin Genitourin Cancer. 2017. PMID: 28655452 Clinical Trial.

2

Immunotherapy for prostate cancer.

Fong L, Small EJ. Fong L, et al. Semin Oncol. 2003 Oct;30(5):649-58. doi: 10.1016/s0093-7754(03)00350-6. Semin Oncol. 2003. PMID: 14571412 Review.

3

Immunotherapy for prostate cancer.

Fong L, Small EJ. Fong L, et al. Curr Urol Rep. 2006 May;7(3):239-46. doi: 10.1007/s11934-006-0027-8. Curr Urol Rep. 2006. PMID: 16630528 Review.

4

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. Small EJ, et al. Among authors: fong l. Mol Ther. 2006 Jul;14(1):107-17. doi: 10.1016/j.ymthe.2006.02.011. Epub 2006 May 9. Mol Ther. 2006. PMID: 16690359 Free article. Clinical Trial.

5

Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.

Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. Rini BI, et al. Among authors: fong l. J Urol. 2006 Jun;175(6):2087-91. doi: 10.1016/S0022-5347(06)00261-8. J Urol. 2006. PMID: 16697809

6

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Rini BI, et al. Among authors: fong l. Cancer. 2006 Jul 1;107(1):67-74. doi: 10.1002/cncr.21956. Cancer. 2006. PMID: 16736512 Free article. Clinical Trial.

7

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. Lin AM, et al. Among authors: fong l, fong k. BJU Int. 2006 Oct;98(4):763-9. doi: 10.1111/j.1464-410X.2006.06396.x. BJU Int. 2006. PMID: 16796694 Clinical Trial.

8

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.

Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. Small EJ, et al. Among authors: fong l. Clin Cancer Res. 2007 Mar 15;13(6):1810-5. doi: 10.1158/1078-0432.CCR-06-2318. Clin Cancer Res. 2007. PMID: 17363537 Clinical Trial.

9

Immunotherapy for prostate cancer.

Fong L, Small EJ. Fong L, et al. Curr Oncol Rep. 2007 May;9(3):226-33. doi: 10.1007/s11912-007-0026-z. Curr Oncol Rep. 2007. PMID: 17430695 Review.

10

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.

Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Ryan CJ, et al. Among authors: fong l. J Urol. 2007 Dec;178(6):2372-6; discussion 2377. doi: 10.1016/j.juro.2007.08.011. Epub 2007 Oct 22. J Urol. 2007. PMID: 17936834 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

664 results

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

664 results